Postmenopause, female APOE4 carriers are also at greater AD risk than their male counterparts (Bretsky et al., 1999; Neu et al., 2017), but it is unknown whether a reduction in neuroprotective ovarian hormones, combined with an elevated cardiometabolic and genetic risk profile, may accelerate brain aging and subsequent AD risk in females compared to males. The gene discussed is APOE; the disease is Alzheimer disease.